I am confused why the Charnley hip which has the most outcome data of all, and has been recognized within the field of orthopaedics as being the most cost effective. This indicates a flaw in design concept for the methodology proposed. Is it that the information needed by the authors to define outcome is not available for most replacement types? This therefore would bias the recommendations more on the method of study rather than the actual outcome of the prosthesis. My fear is that policies may be made within health systems as administrators are even less able to understand the complexity of choice of medical devices and mandate this method without appropriate consultation.
However equally publication of this paper may create a greater degree of standardization and interest in producing QUALY's as an outcome measure for all joint replacements. Currently most joint registries do not record outcomes except revision rates. This paper would indicate that we should move in this direction and the potential improvement in process would vastly outweigh the cost required to collect the data. However as always it is not clear who is going to pay for this. These concepts I think would be more readily apparent to the authors if an orthopaedic surgeon was a co author. My reason for suggesting a major revision is I suggest that the authors go back and obtain an orthopaedic surgeon (ideally one with joint registry experience or with experience in outcomes of hip joint replacement) and write the paper more based on the complexity of the procurement process that has different complexities and issues than a drug. Overall I think the concept is sound and is a great way to deal with the dillema of outcome vs cost and ultimately is where we need to go in the future for choice of devices -the issue lies in quality and methods for determining outcomes of medical devices with many papers not recording outcomes in a way that is standardized enough to be used for this type of modelling, and the long cycle (15 years) to determine outcomes for orthopaedic devices. POINT#1: "This paper shows how the evidence on benefits and costs could be used to manage tenders for medical devices. In principle the topic is interesting, but the case used it's not the best example: benefits are set equal across devices and cost-minimization would be better." Authors' response: Reviewer 2 argues that benefits were set equal across devices. This is not exactly what our analysis shows because differences between devices existed in our results, but were minimal (in the order of 0.0001 QALYs up to 0.0002 QALYs). Anyhow, since differences in benefits were very small in our analysis, this can justify the conclusion that "benefits were [….] equal across devices and cost minimization would be better". On the one hand, when we initially chose the data of Pennington et al as an example for our analysis, we could not predict this type of (negative) result in terms of (poor) suitability of Pennington's data-set to highlight the advantages of the "our method". In other words, while "our method" is aimed at converting differences in benefit into differences in tender scores, the choice of Pennington's data-set as an example (with its three classes of prostheses including three devices each) is unfortunate because in this data-set differences do not virtually exist. Hence, we recognise that this observation made by Reviewer 2 is correct and, for this reason, we have introduced an additional analysis including the 9 devices in a single group, which is presented in Table 4 (see below). In the new analysis of Table 4 , differences between devices are in the order of 0.2 QALYs; this allowed us to underscore how "our method" can handle the presence of not negligible differences in benefits across devices.
VERSION 1 -AUTHOR RESPONSE
POINT#2: "Methods -The authors should better clarify how the two studies among the 51 were selected (Page 8, 7)" Authors' response: As we have explained in the discussion, the focus of our paper was on the strategy of extending HTA methods from drugs to implantable devices, and from reimbursement decisions by payers to tender decisions by hospitals. Since the phase of literature search was not the core of our analysis, we admit that the selection process we adopted was a simplified one. On the other hand, it should be stressed that our intention was not to select a series of studies for inclusion in a systematic review or in a meta-analysis, but simply to select a SINGLE study for use as our source of information for the modelling section and the simulated tender. While we recognise that the quality of our literature search is questionable, on the other hand it is important to emphasise that the objective of our literature search was not to provide a comprehensive description of the current literature on this topic, but simply to select a SINGLE study for use in our subsequent calculations.
POINT#3: "-It's not clear the process used to extract data from the selected paper: what does a consensus value for each item mean? (Page 5, 59)" Authors' response: Our original papers was quite unclear on this point; we simply meant that the extraction of data was verified in duplicate to ensure that the correct values were extracted.
POINT#4: "-It is unclear how the authors have estimated QALYs and NMB according to the procedures (ii) and (iii) quoted at page 7 (5-12)" Authors' response: We have added further details on this point. We confirm that both QALYs and NMBs were recomputed using the Markov simulation model described in Reference 12. Anyhow, our recomputed values were close to those originally published by Pennington and co-workers.
POINT#5: "The outcome (QALYs) is described, but the description of other treatment-related costs (Page 6, 32-43) is quite confused… […….] In principle, the results address the research question, but utility (and QALYs) have been set equal across devices (due to very small differences among devices): instead of calculating NMB the authors could carry out a cost minimization analysis (or set the score on the ground of costs)". Authors' response: Actually, utilities (but not QALYs) were set equal across devices; in more detail, the estimates of QALY were not equal across the different devices because, since the model incorporated different revision rates for different devices, the final values of QALY reflected these differences in the revision rates and therefore differed from one another (and so, in other words, they kept a device effect on this parameter). We recognise that, in the context of our study, setting QALYs equal across different devices would make little sense (and would justify a CMA), but this was not the case. On the other hand, the differences in QALYs were of minimal magnitude, but the implications of this finding have already been addressed in our response to Point#1 made by Reviewer 2.
POINT#6: "The way the authors have carried out the simulation on the grounds of the selected article should be better described." Authors' response: We have tried to improve the description of this section of our study.
POINT#7: "Written English is not acceptable."
Authors' response: The quality of the English has been improved throughout the manuscript. REVIEWER: 3 Reviewer Name: Alastair Younger Institution and Country: University of British Columbia, Vancouver, Canada Please state any competing interests: No competing interests directly -I do receive minimal consulting fees for bone graft substitutes, an ankle replacement design, and fracture prosthesis designs. I receive funds to perform outcome research on bone graft substitutes, an MTP joint replacement, and screw designs POINT#1: "Abstract -Exeter misspelled" Authors' response: We have corrected this error.
POINT#2: "The monetary value in pounds does not make sense-most hip replacements cost the hospital in the region of 2 to 3 digits -IE between 200 to 1000 pounds -I therefore am struggling to understand the figure quoted.
Authors' response: While the cost "between 200 to 1000 pounds" is likely to be the unit cost of the device, the study by Pennington et al was aimed at computing all direct costs (including the device cost). In other words, it is true that the device cost would be in the range of 200 to 1000 pounds, but the data of Pennington et al were aimed at computing all direct costs. However, the real problem is that these values of cost per patient were nearly identical with one another, and so they did not contribute to create differences in cost between different products. On the other hand, it should be stressed that, since no evidence from the literature was available to support a different cost across these devices, the estimates presented by Pennington et al., which were very close to one another, should be assumed to be correct.
POINT#3: "Review of the tables shows that the net [monetary] benefit per patient is large in comparison to the prosthesis cost, and there is very little difference between the values. This indicates that the cost of the hip replacement has little to do with the overall cost or benefit of care. However this also supports the authors initial concept that the cost of the hip replacement should not be the only determinant of choice -outcomes also should be factored in." Authors' response: As pointed out in our response to Point#1 made by Reviewer 2, the first impression in examining the QALYs per patient associated to the 9 devices is that there is very little difference between the values estimated for the different devices. About these small differences, also in our initial manuscript we had observed that "Firstly, the role of <> in the comparison across the various device scores should be interpreted correctly.
For example, the values of NMB for individual devices were very similar one another, and consequently the differences between the device-specific values of NMBs were small, particularly when they were expressed as percentages in relation to the size of NMB………". Again, the point is that, while our NMB model can manage differences in either cost per patient or QALYs per patient or both, the data resulting from Pennington's paper did not show any meaningful difference in these parameters. So, after examining the results of our analysis, the example selected for our analysis example proves to be an imperfect example. This limitation of our study has been emphasized more clearly in the revised manuscript. As previously observed, to overcome this limitation, we have performed an additional analysis presented in Table 4. POINT#4. "Introduction [………………..] Because it takes so long to obtain an outcome,[……….] many of the devices may be obsolete by the time the outcome is obtained. As a result the innovation cycle is a lot shorter than the outcome cycle. In medication the reverse is true -the innovation cycle is long and the outcome reporting is much more short term (such as for a blood pressure medication). For joint replacement an early failure mode such as aseptic loosening will result in the withdrawal of a prosthesis from the market, and a new design. The new design may be more effective and more costly (because of the costs of launch) and the model proposed would prevent innovation. Because the major cost in a new design is launching older orthopaedic devices will be much more cost effective and therefore are usually preferred in a cost contained system." Authors' response: This consideration is correct. However, we do not agree that "…in medication the reverse is true -the innovation cycle is long and the outcome reporting is much more short term-" because there are numerous examples (e.g. anti-cancer drugs given with curative intent) where outcomes are long-term.
POINT#5: "I am confused why the Charnley hip which has the most outcome data of all, and has been recognized within the field of orthopaedics as being the most cost effective" [is not mentioned]. "This indicates a flaw in design concept for the methodology proposed".
Authors' response: We confirm that the Charnley prosthesis is a widely used device for hip replacement (see for example: Caton JH et al. Int Orthop. 2014; 38:1125-9) . However, this device has not been mentioned in the study by Pennington et al.
On the other hand, we stress again that, in our analysis, the phase of literature search has a marginal importance because the core of our paper is to describe an evidence-based method of procurement and to present an example of its application based on real-life data.
POINT#6: "[…………]
Is it that the information needed by the authors to define outcome is not available for most replacement types? This therefore would bias the recommendations more on the method of study rather than the actual outcome of the prosthesis. My fear is that policies may be made within health systems as administrators are even less able to understand the complexity of choice of medical devices and mandate this method without appropriate consultation." Authors' response: This observation ("the information needed by the authors to define outcome is not available for most replacement types") is correct. We have stressed this point in our revised paper.
POINT#7: "However equally publication of this paper may create a greater degree of standardization and interest in producing QUALY's as an outcome measure for all joint replacements. Currently most joint registries do not record outcomes except revision rates. This paper would indicate that we should move in this direction and the potential improvement in process would vastly outweigh the cost required to collect the data. However as always it is not clear who is going to pay for this." Authors' response: Likewise, we agree on the limitation that "…currently most joint registries do not record outcomes except revision rates." Also this point has been mentioned in our revised Discussion.
POINT#8: "This paper would indicate that we should move in this direction and the potential improvement in process would vastly outweigh the cost required to collect the data. However as always it is not clear who is going to pay for this." Authors' response: We have pointed out that it is not clear who is going to pay for the need to collect the data on outcome.
POINT#9: These concepts I think would be more readily apparent to the authors if an orthopaedic surgeon was a co author. My reason for suggesting a major revision is I suggest that the authors go back and obtain an orthopaedic surgeon (ideally one with joint registry experience or with experience in outcomes of hip joint replacement) and write the paper more based on the complexity of the procurement process that has different complexities and issues than a drug.
Authors' response: Considering the strict deadline set by the Editors of BMJOpen for completing our review, we did not find any orthopaedic surgeon who could collaborate in this analysis by working on it in August 2017, which is a holiday season in Italy. In contrast, we invited Dr.Claudio Marinai, who coordinated the "tender college" formed two years ago in the Tuscany Region to run the latest tender on hip prosthesis (this group included also two orthopaedic surgeons); Dr.Marinai has helped us with the present revision of our paper and therefore appears as a co-author of the revised paper.
POINT#10: "Overall I think the concept is sound and is a great way to deal with the dilemma of outcome vs cost and ultimately is where we need to go in the future for choice of devices -the issue lies in quality and methods for determining outcomes of medical devices with many papers not recording outcomes in a way that is standardized enough to be used for this type of modelling, and the long cycle (15 years) to determine outcomes for orthopaedic devices." Authors' response: We agree on the need to standardize the collection of data for this type of modelling. We also agree that the long cycle (15 years) to determine outcomes for orthopaedic devices has a strong influence on the results of the approach described in our paper. We have emphasised these points in the revised Discussion. We have also mentioned an observation that we have recently published regarding this problem (Messori A, Trippoli S, Marinai C. Effectiveness of interventions based on implantable devices: meta-analyses or systematic reviews that fail to indicate which device brands were used. Evidence Based Medicine 2017, in press; preprint available at http://www.osservatorioinnovazione.net/papers/ebmed2017.pdf ). Estimating resources 13a Single study-based economic evaluation: Describe approache -SEE 13b and costs used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost.
Describe any adjustments made to approximate to opportunity costs. 13b Model-based economic evaluation: Describe approaches and -WE RELIED ON THE data sources used to estimate resource use associated with MODEL DEVELOPED BY model health states. Describe primary or secondary research -PENNINGTON, BUT SOME methods for valuing each resource item in terms of its unit cost RESULTS WERE RECOMPUTED; Describe any adjustments made to approximate to opportunity costs OPPORTUNITY COST WERE NOT EXAMINED.
Currency, price date, 14 Report the dates of the estimated resource quantities and unit SEE REFERENCE 9; and conversion costs. Describe methods for adjusting estimated unit costs toNO ADJUSTMENT OF COSTS the year of reported costs if necessary. Describe methods for TO A SPECIFIC YEAR; converting costs into a common currency base and the exchange rate. Choice of model 15 Describe and give reasons for the specific type of decision THE MODEL HAS ALREADY analytical model used. Providing a figure to show model structure is BEEN DESCRIBED strongly recommended.IN PREVIOUS PAPERS; Assumptions 16Describe all structural or other assumptions underpinning the decision-analytical model.
Analytical methods 17 Describe all analytical methods supporting the evaluation. This DESCRIBING THE MODEL could include methods for dealing with skewed, missing, or WAS NOT AN OBJECTIVE censored data; extrapolation methods; methods for pooling OF OUR ANALYSIS data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty. 
